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Abstract: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is asso-
ciated with significant morbidity and mortality. At the societal level, AF carries an enormous 
cost. Strategies aimed at reducing AF morbidity and mortality and containing the associated 
fiscal burden are of paramount importance. This review will discuss AF treatment strategies and 
economics, focusing on the impact of dronedarone, a novel antiarrhythmic agent.
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Introduction
Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia affecting 
three million Americans with prevalence expected to reach ten million by 2050.1–3 
Its occurrence rises with age with as many as 10% of the population over 80 years 
of age afflicted. It is responsible for most arrhythmia-related hospitalizations and 
leads to the greatest length of hospital stay associated with any disorder of the 
cardiac rhythm.4
While asymptomatic in some patients, AF is a source of significant disability in 
others. It may present with palpitations in younger patients with preserved diastolic 
function, less dependent on atrial contraction, and with symptoms of congestive heart 
failure in patients with hypertension or cardiomyopathy, where controlled heart rate 
and atrial “kick” are of paramount importance to ventricular filling.5 AF is responsible 
for up to 30% of all ischemic strokes, a source of significant disability and   mortality 
in these patients.6 The risk of stroke is higher in AF patients over 75 as well as in 
patients with history of hypertension, diabetes, congestive heart failure, and prior 
embolic events, all commonly present in this group.7 Among patients enrolled in the 
Framingham study, mortality in AF patients was higher by a factor of 1.5 among men 
and 1.9 among women.8
Apart from its clinical impact, AF carries an enormous fiscal burden. This relates to 
the cost of physician visits, hospital admissions, tests and invasive procedures, medica-
tions and over-the-counter alternatives, as well as the cost related to the treatment of 
comorbidities and complications. Several recent studies have gone beyond addressing 
these issues and reported on the lost productivity related to AF, ranging from 9 to 
26 days of work per year with a significant increase in short-term disability.9
Strategies aimed at reducing AF related complications and costs are critical and 
will be discussed in this review with focus on the impact of dronedarone.
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Current strategies  
in the management of AF
Management strategies for AF fall into one of three main 
categories – symptom relief and management of congestive 
heart failure, prevention of thromboembolic complications, 
and rate control. All of these deserve to be addressed in each 
individual patient, while strategies used to address one of 
these areas may also help to impact others.
Symptom relief most commonly comes in the form of 
rate control in patients with persistent or permanent forms 
of AF, while patients with the paroxysmal form of this con-
dition may benefit from rhythm control in order to improve 
their quality of life. There is little evidence that one strategy 
is superior to the other in terms of morbidity or mortality, 
however, it is clear that patients who are in fact able to stay 
in rhythm do better over time.10–12
Unfortunately, rhythm control in AF patients can only be 
achieved with antiarrhythmic medications 40%–60% of the 
time because of their limited efficacy and significant associated 
side effects.13 Amiodarone, the most effective antiarrhythmic 
medication on the market, is also the most toxic, negatively 
affecting a variety of organ systems. Its efficacy comes in 
part from an extremely long half-life, which may allow the 
patient to miss several doses of amiodarone without any 
noticeable clinical impact. At the same time, toxicities related 
to amiodarone are cumulative and the likelihood of adverse 
events goes up with the duration of exposure and total dose 
administered over time.14 Other antiarrhythmic medications 
may be outright dangerous in certain populations. Sotalol and 
dofetilide may lead to QT interval prolongation and ventricular 
fibrillation in some patients and cannot be administered to 
patients with renal dysfunction. Sotalol is poorly tolerated 
by patients with congestive heart failure and may result in 
disabling fatigue in others. Class I agents such as flecainide 
and propafenone may cause ventricular tachyarrhythmia 
in patients with structural heart disease and, particularly, 
those with history of ischemic cardiomyopathy. These drugs 
can also convert AF to atrial flutter and   paradoxically, by 
lowering the atrial rate, facilitate 1:1 atrioventricular (AV) 
nodal conduction. Safe administration of Class I drugs 
involves co-administration of AV nodal blocking agents. 
Unfortunately, sotalol, and other AV nodal blocking agents 
which may be used for rate control, or co-administered with 
Class I agents, can exacerbate sinus node dysfunction, highly 
prevalent among patients with AF, and potentially lead to the 
need for permanent pacemaker placement.15
Ultimately, catheter ablation for AF has developed over 
the last decade to help alleviate symptoms. While superior 
to antiarrhythmic drugs this approach does not appear to 
offer a cure to a number of patients, but rather appears 
to delay   progression of the disease and does carry with it up 
to 4.3% risk of significant complications based on a recently 
  published worldwide survey of the ablating centers.16,17
Rate-control strategy, while important to consider in 
symptom management, has an independent value as well. 
Some AF patients react poorly to the rapid AV nodal 
conduction and develop so called “tachycardia-mediated” 
cardiomyopathy. These patients may suffer from conges-
tive heart failure or may present without symptoms but with 
clear deterioration in their left ventricular ejection fraction. 
  Fortunately, at least in some patients changes reverse with 
adequate rate control. The concept of what rate qualifies as 
adequate has seen some changes recently as the investigators 
of the RACE II trial reported little difference between aggres-
sive rate control targeting a resting rate of 80 beats per minute 
(bpm) and the more lenient approach aiming at 110 bpm.18 
Most patients in either arm of the study ended up with a 
ventricular rate below 100 bpm, a cutoff incorporated into 
the recently revised Canadian Cardiovascular Society guide-
lines on AF management.19 Rate control is typically achieved 
with AV nodal blocking agents such as beta blockers and 
non-dihydropyridine calcium channel blockers, but there is 
still room for the less effective digitalis, particularly among 
heart failure patients, those with diminished left ventricular 
ejection fraction, or as a second or third line agent.
Prevention of embolic complications is the most impor-
tant aspect of care for AF patients. These range from transient 
ischemic events (TIA) to strokes and are the most costly 
complication of AF. Strokes secondary to AF are more severe 
than those secondary to atherosclerotic disease and impart a 
greater disability on the victims.20 This results in significant 
costs related to hospitalizations, rehabilitation, and chronic 
disability. Strategies aimed at reducing embolic events in AF 
patients include therapy with aspirin, combination of aspirin 
and clopidogrel, and oral anticoagulant therapy with warfarin 
or one of the new agents targeting either thrombin or Factor 
Xa.21–23 While effective from the point of view of preventing 
strokes and other embolic events, one must be aware of the 
significant risk of bleeding associated with these agents used 
alone, and especially, in combination.
One other strategy aiming to minimize the risk of embolic 
events involves mechanical elimination or closure of the 
left atrial appendage, the area where clots related to AF 
most commonly form. Techniques for left atrial appendage 
closure or excision have been initially developed by the car-
diac surgeons.24 Novel left atrial appendage closure devices 
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have recently shown promise in reducing the risk of stroke 
in patients who cannot take antithrombotic agents and can 
be placed percutaneously.25
Cost of AF and its management
A number of studies have looked at the costs related to AF 
across the world. One must be cautious when evaluating their 
findings since the data comes from a potpourri of sources 
ranging from administrative databases, to multicenter and 
national registries, to single center studies. Patient popula-
tions described are also heterogeneous and range from the 
relatively young and healthy but highly symptomatic patients 
presenting for AF ablation, to older patients admitted to the 
hospitals with embolic sequelae of AF.
Multiple negative health outcomes in AF patients as well 
as AF treatment strategies contribute to an ever-growing 
tap drawn on the healthcare system and the society at large. 
A recent systematic review of the cost of AF care revealed 
that the overall average annual cost to manage one AF patient 
is US$7015 in 2010 with a range of estimated costs as high as 
just over US$10,000.26 While these costs are substantial, they 
represent only about one quarter of the entire health system 
costs for patients with AF. A German study estimated the 
entire annual cost of care for patients with a stroke secondary 
to AF at $20,613.27 While an American study estimated annual 
cost of care for an AF patient at $40,169.6 Hospitalizations 
are the most important determinant of the total cost (58%) 
with the cost of a single acute admission in Ontario with AF 
as a primary diagnosis of US$23,392 in 2010.28 Similarly, 
direct costs attributable to AF in the US, based on the findings 
from an insurance database, were $15,553 per year in 2002 
with 75% of the cost related to in-patient care.26,29 Each AF 
related hospitalization in another group of Medicare insured 
patients cost an average of US$11,085 (2004–2007), further 
supporting these findings.30 To make matters worse, 50% of 
the AF patients may be readmitted within a year, leading to 
further rising costs.
A number of AF cost estimates have been published 
internationally. In a recent analysis of a German insurance 
database, close to 80% of the cost of care in the first year 
following an AF related hospitalization was due to the index 
event with 15% attributable to the cost of drugs, and 3% to 
the outpatient care.31 The cost of non-traditional adjuvants 
and remedies as well as that of sickness benefits, typically 
not included in other AF cost analyses, was on par with the 
cost of outpatient care – contributing about 4% of the overall 
treatment cost, which came in at an astounding 7,688 ± 954 
Euro per patient in 2005 currency.
It does not come as a surprise that the cost reported using 
administrative databases is substantially higher than the 
estimates from surveys and “back of the envelope” exercises 
reported for a number of geographies. Euro Heart Survey 
on AF published estimated annual costs of AF care ranging 
from €698 in Poland to €1544 in the Netherlands in 200632 
or an annual cost of care in an AF patient of US$4840 in 
2005 previously estimated by our group.33 Treatment costs 
associated with follow-up of AF patients including hospital 
admissions, emergency room visits, testing, and follow-up 
with cardiologists, internists, and family physicians were 
also reported in France.34 This analysis stratified patients 
according to therapeutic strategy – rate or rhythm control – 
as well as according to concomitant congestive heart failure 
symptoms. The authors estimated the average total 5-year 
cost of AF at €16,539 in 1998 currency.
The real cost of care for an AF patient likely lies some-
where in between with surveys underestimating some of 
the less apparent cost contributors and counting AF as the 
primary diagnosis responsible for treatment and associated 
costs, and administrative databases overestimating costs 
related to AF as a secondary diagnosis in typically older 
and sicker cohorts of insured patients than those studied in 
the surveys.
As a result, system cost attributable to AF is staggering 
with over US$2 billion spent only on the care of patients 
with AF-related strokes in the US Medicare system and a 
total estimated medical expenditure related to AF around 
US$6.5 billion per year.26
Cost containment strategies
A number of studies have looked at the potential cost contain-
ment strategies. Of these the most obvious is greater attention 
to anticoagulation therapy in these patients. The bulk of the 
current cost of AF care is related to thromboembolism, yet 
currently as few as 10%–20% of the AF patients are treated 
with appropriate prophylaxis strategies.35 Those who do 
take oral anticoagulants spend much of their time taking 
subtherapeutic doses of the medication placing them at risk 
of stroke, while others take supertherapeutic doses and run a 
significant risk of bleeding given a very narrow therapeutic 
range of these drugs. Novel antithrombotic agents allow 
for more consistent anticoagulation and have been shown 
superior to warfarin in stroke prevention.
In the study of Dagibatran versus Warfarin in Patients 
with Atrial Fibrillation (RELY) the use of dabigatran, a direct 
thrombin inhibitor, was associated with similar rates of stroke 
and systemic embolism but lower rate of major   bleeding 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
69
Dronedarone and cost of AF managementClinicoEconomics and Outcomes Research 2012:4
compared to warfarin at a lower dose of 110 mg, while the 
higher dose of the drug at 150 mg was associated with lower 
rates of stroke and systemic embolism but similar rates of 
major bleeding compared to warfarin.23 Similarly, in the study 
of Apixaban versus Warfarin in Patients with Atrial Fibrillation 
(ARISTOTLE), apixaban, a factor Xa inhibitor, was superior 
to warfarin in preventing stroke or systemic embolism, caused 
less bleeding, and resulted in lower mortality.36 Based on their 
better safety profile these medications will likely result in 
further savings compared to warfarin. Indeed, when analysed 
within the Canadian healthcare system, the incremental cost 
effectiveness ratio (ICER) of dabigatran was $10,440/ quality-
adjusted life-years (QALY) versus warfarin and $3962/ QALY 
versus “real-world” prescribing.37 The estimates were more 
conservative within the UK healthcare system at £23,082–
£42,386/QALY.38 A similar US analysis found it to be less 
so at an ICER of $86,000/QALY.39 The differences between 
these are explained by different stratification of the patients by 
CHADS-2 score and assumptions with respect to INR control 
and are beyond the scope of this paper.
Another such strategy has to do with ablation. First 
promise for a potential cure for AF came in 1998 when it 
became apparent that ectopic atrial activity originating in 
the pulmonary veins may be responsible for initiation of 
AF and could be targeted with radiofrequency energy.40 The 
field of targeting AF triggers has seen substantial progress 
since this discovery with multiple tools coming to market 
over the last decade in an effort to improve the safety and 
efficacy of these procedures. Most of these strategies involve 
delivering various types of energy just proximal to the 
insertion of the pulmonary veins into the left atrium using 
conventional, irrigated tip, circular, and balloon shaped 
catheters. Another strategy that was first described in 2004 
and has seen much technological attention has been that 
of targeting tissues thought to perpetuate AF or presenting 
so called AF substrate.41 These latter efforts have focused 
on elimination of the viable atrial myocardium displaying 
particularly disorganized activity during AF, or delivering 
energy over autonomic nerve ganglia thought to initiate and 
perpetuate the arrhythmia.42
These approaches have shown promise in a multitude of 
individual center and multicenter randomized trials uniformly 
showing clinical benefit of ablation over antiarrhythmic drug 
therapy with respect to sinus rhythm maintenance, quality of 
life, and arrhythmia related hospitalizations in at least some 
populations.16,43,44
Several projections of cost of care of an AF patient have 
been published in an attempt to estimate the relative cost of 
ablation and contrast it to the cost of medical therapy over 
time. A study directly comparing the costs of ablation and 
medical therapy in the Canadian healthcare environment 
has been published.33 Costs related to medical therapy in 
the analysis included the cost of anticoagulation, rate and 
rhythm control medications, non-invasive testing, physician 
follow-up visits, and hospital admissions, as well as the cost 
of complications related to this management strategy. Costs 
related to catheter ablation were assumed to include the cost 
of the ablation tools (electroanatomic mapping or intracardiac 
echocardiography-guided pulmonary vein ablation), hospital 
and physician billings, costs related to periprocedural 
medical care and complications. Costs related to these 
various elements were obtained from the Canadian Registry 
of Atrial Fibrillation (CARAF), government fee schedules, 
and published data. Sensitivity analyses looking at a range 
of initial success rates (50%–75%) and late attrition rates 
(1%–5%), prevalence of congestive heart failure (20%–60%), 
as well as discounting varying from 3% to 5% per year were 
performed. In this study, the cost of catheter ablation strategy 
ranged from ∼US$14,000 to US$18,000 in 2005 currency. 
It was assumed that patients who required anticoagulation 
prior to ablation would continue on this therapy following the 
procedure with an annual average follow-up cost of US$1400 
to US$1800 among the ablated patients. The annual cost of 
medical therapy ranged from US$3600 to US$4300. The latter 
estimate was supported by the findings from the FRACTAL 
registry which prospectively collected clinical and cost data 
for 973 patients with AF.45 The study projected costs of 
ongoing medical therapy and catheter ablation to equalize 
at 3.2 to 8.4 years of follow-up in this study but did not take 
into account development of the novel antiarrhythmic and 
thromboprophylactic strategies not available at the time of 
the publication.
Four papers attempted to perform a cost-benefit analysis 
of AF ablation with that of medical therapy. In the first of 
these studies, a Markov decision analysis model looking 
at 55- and 65-year-old cohorts of patients at low and 
moderate risk of stroke was created by the investigators.46 
Complications and costs related to AF, medical therapy, and 
catheter ablation were accounted for. The model assumed 
that amiodarone would be used for rhythm control and a 
combination of digoxin and atenolol for rate control. Eighty 
percent efficacy of AF ablation was assumed with 30% 
redo rate during the first year and 2% per year late success 
attrition rate. It was further assumed that as many as 38% of 
the patients on rate control would convert to sinus rhythm 
with annual AF relapse rate of 5%. Moderate risk of stroke 
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was defined as having one risk factor, including diabetes, 
hypertension, coronary artery disease, or congestive heart 
failure. Patients at low risk of stroke were assumed to have 
no such risk factors. For the purpose of the model, patients 
at moderate risk of stroke were anticoagulated whereas 
those at low risk could be on warfarin or aspirin. The model 
incorporated an annual stroke risk of 2.3% and 1.1% for 
patients treated with aspirin and 1.3% and 0.7% for those 
on warfarin at moderate and low risk for stroke respectively. 
A relative stroke risk of 1.4% per decade was accounted for. 
Age adjusted mortality based on life tables and mortality 
reductions attributable to aspirin and warfarin were accounted 
for. All healthcare costs were calculated in 2004 US dollars 
using 3% discounting per year. Costs were estimated based 
on Medicare reimbursement rates, hospital accounting 
information, published literature, and the Red Book for 
wholesale drug costs. Catheter ablation appeared to be most 
cost-effective in younger patients at moderate risk of stroke at 
$28,700/QALY gained. It was somewhat less cost effective in 
the older moderate risk patients at $51,800/QALY gained and 
least cost-effective among the younger patients at low risk 
of stroke at $98,900/QALY gained. Unfortunately, since no 
evidence has been presented to date on the efficacy of ablation 
for prevention of thromboembolic events, the findings of 
this study are conditional on such evidence coming to light 
in the years to come.
Eckard et al developed a decision-analytic model to 
estimate costs, health outcomes, and incremental cost-
effectiveness of RFA compared to AAD treatment for AF for 
a lifetime time horizon.47 The authors used a decision tree for 
the initial year in which the RFA procedure was assumed to 
take place, and a long-term Markov structure for subsequent 
years. The authors factored in the potential for a second 
ablation within a year of the first procedure in patients still 
suffering from AF. They assumed 70%–80% ablation success 
within the first year with 1.4 ablations per patient required to 
maintain rhythm based on Swedish data. The cost of ablation 
was estimated at around US$12,000 in 2006, including the 
cost of 3–4 days in hospital, all diagnostic examinations 
necessary as well as the cost of disposables. Annual cost of 
AF therapy was estimated at US$2000. In order to estimate 
QALY weights for different health states, age-adjusted 
QALY weights based on a Swedish general population were 
applied for patients in the controlled AF state, and used as 
reference points. A decrement of 0.1 for uncontrolled AF 
and 0.25 for stroke was applied to the baseline utility in 
the controlled AF state. With annual success attrition rates 
of 5%, 10%, and 15% used in the sensitivity analysis, the 
relative cost of ablation was estimated up to US$58,000 per 
QALY without assuming stroke prevention related to the 
ablation strategy.
A similar analysis in the United Kingdom suggested 
incremental cost effectiveness of ablation at US$16,000 per 
QALY in 2008. The authors of this paper assumed freedom 
from AF at 84% at one year with 2%–4%/year rate of suc-
cess attrition over time resulting in their estimates favoring 
ablation over the other published economic analyses. Further 
sensitivity analyses found the estimate to depend significantly 
both on the relative quality of life estimate associated with 
sinus rhythm and on the prognostic implications of being 
in rhythm.48
Finally in a more recent paper, Reynolds and his group 
published a Markov model cost effectiveness analysis of 
ablation versus antiarrythmic therapy in a simulated cohort of 
patients with paroxysmal drug refractory AF projected over 
5 years. The authors assumed 60% success of the ablation 
approach with a 25% rate of repeat ablation. Utilities for 
quality of life assessment were derived from real-life data, 
using the FRACTAL registry for the medically treated patients 
using SF-12 and patients ablated at the authors’ institution, 
as well as those enrolled in the A4 trial for derivation of the 
scores in this cohort based on the SF-36 questionnaire. In the 
base scenario, the incremental cost per QALY among ablated 
patients was US$47,333 in 2009 with cost neutrality achieved 
at ∼10 years taking into account 3% discounting.49
At the same time, given that the most expensive aspect 
of AF care relates to hospitalizations, strategies which may 
decrease the need for, and the length of, hospitalizations 
would be expected to lead to a significant reduction in the 
economic burden of AF.
Impact of dronedarone
Dronedarone is a novel antiarrhythmic agent developed on 
the basis of the amiodarone molecule.50 Pharmacologically, 
the molecule of dronedarone does not carry iodine, thought 
to account for most of the end-organ toxicity seen among 
amiodarone-treated patients. It was also modified to make 
it more hydrophilic and to expedite elimination half-life 
compared to its parent drug. Dronedarone had undergone 
extensive clinical testing in multiple trials and was shown to 
have rhythm control efficacy comparable to that of sotalol or 
class Ic agents (Table 1). In addition dronedarone has been 
shown to provide a measure of rate control, lowering heart 
rate in AF among treated patients by an average of 14 bpm.51 
Unlike other antiarrhythmic agents, dronedarone may be 
started on an outpatient basis without the need for in-patient 
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alone (including beta blockers and anticoagulation). When 
dronedarone was evaluated as a second-line treatment option, 
the comparators were the antiarrhythmic drugs amiodarone, 
sotalol, and class Ic drugs, depending on the type of AF and 
baseline risk factors.
The model used a lifetime time horizon and included 
four health states: normal sinus rhythm, permanent AF with 
uncontrolled symptoms, permanent AF with controlled 
symptoms, and death. From the normal sinus rhythm state, 
people could move to any of the other states. From the two 
permanent AF health states, people could move between 
these states or to death. Transition between health states was 
determined by the following events: AF recurrence, acute cor-
onary syndrome, stroke, congestive heart failure, treatment 
discontinuation, change in symptoms (for the permanent 
AF states), or death. The baseline risk of these events was 
taken from the ATHENA trial, extrapolated to a lifetime time 
horizon and adjusted for each treatment arm using odds ratios 
from the mixed treatment comparison. All-cause mortality 
was estimated using age-specific UK life tables and adjusted 
for CHADS-2 score. The risk of death after stroke and con-
gestive heart failure events was estimated using published 
sources. The model also included adverse events associated 
with each treatment.
Drug costs were derived from the “British national 
formulary” (edition 57). Drug administration costs for 
dronedarone consisted of a specialist outpatient visit for 
treatment initiation and a GP visit for a day-7 creatinine test 
(£213). For comparators, it was assumed that hospitalization 
was required for treatment initiation (£249) and 6-monthly 
GP visits and tests were required for monitoring (£58–£76 
depending on the treatment). Costs for the majority of health 
events occurring in the model were taken from published 
literature. Most events were assumed to incur a one-off cost; 
but for stroke and congestive heart failure, ongoing daily 
costs were assumed. Costs for adverse events came from 
NHS Reference Costs 2007–2008. A proportion of adverse 
events were assumed to require hospitalization (based 
on expert clinical opinion) and the rest were assumed to 
require an outpatient consultant visit. For short-term adverse 
events, a one-off cost at treatment initiation was incurred 
and for adverse events with lifetime effects, a 6-monthly GP 
visit was assumed to be required. Data on resource use were 
sourced from clinical opinion and published literature.
In the base-case analysis, the incremental cost-
  effectiveness ratios (ICERs) for the analysis of dronedarone 
if given in addition to standard baseline therapy (for people 
with a CHADS-2 score of 4 or more) compared with   standard 
monitoring required for sotalol, propafenone, flecainide, and 
dofetilide.
ATHENA, a double blind placebo controlled trial studied 
the effects of dronedarone in addition to standard therapy 
in patients with risk factors including age over 75, or age 
under 75 with at least one of hypertension, diabetes, stroke 
or TIA, enlarged left atrial dimension (.50 mm), or reduced 
left ventricular ejection fraction (,40%).52 Dronedarone was 
shown to reduce AF related hospitalizations with a hazard 
ratio of 0.626 compared to placebo,53 in a similar population 
to that reported by Reinhold and colleagues.31 Dronedarone 
also reduced duration of hospitalization and the risk of stroke 
in these patients by close to 40%. Both of these effects would 
potentially reduce the cost of care by €2875 per patient per 
year based on the German data or approximately US$3000–
6000 based on the US and Canadian data.
In a study of the Humana registry of patients and physicians, 
the authors administered an AF continuing medical education 
(CME) activity, which included information on ATHENA, 
to the participating healthcare providers (unpublished data). 
They then independently tested whether the physicians 
internalized the information provided in the CME and looked 
at the costs of AF management before and after CME was 
administered. Study participants demonstrated a significant 
gain in knowledge and confidence related to the care of AF 
patients following CME. The authors were able to show that 
the use of dronedarone increased 2.5-fold   during the study 
period, whereas little changed with respect to the use of oral 
anticoagulants in the study with only 49% of the guideline-
eligible patients on this therapy. Nevertheless, there was a 
significant decline in the number and duration of AF-related 
hospitalizations and a corresponding decline in AF-related 
healthcare expenditure.
A cost-effectiveness analysis using a discrete event 
simulation that predicts a person’s course if they are treated 
with dronedarone compared with the predicted course with 
alternative treatment pathways was included as part of the 
regulatory submission to the British National Institute for 
Health and Clinical Excellence (NICE).54 In this analysis 
patients were stratified depending on their type of AF and 
baseline risk factors into five groups: paroxysmal AF without 
structural heart disease, paroxysmal AF with coronary heart 
disease, paroxysmal AF with left ventricular dysfunction, 
persistent AF without structural heart disease, and persistent 
AF with structural heart disease. When dronedarone was 
evaluated as part of a first-line treatment for people with a 
CHADS-2 score of 4 or more (in addition to standard base-
line therapy), the comparator was standard baseline therapy 
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baseline therapy alone ranged from £6757 to £7890 per 
QALY gained (incremental costs £3053 and £3307 and 
incremental benefits 0.45 and 0.42 QALYs for these two 
ICERs respectively). The ICERs varied depending on the 
type of AF and the presence of structural heart disease, 
coronary heart disease, or left ventricular dysfunction. For 
the analysis of dronedarone as an alternative antiarrhythmic 
drug to amiodarone, the ICERs were £2645 per QALY 
gained (incremental cost £3528 and incremental benefit 1.33 
QALYs) for paroxysmal AF with left ventricular dysfunction 
and £3113 per QALY gained (incremental cost £3986 and 
incremental benefit 1.28 QALYs) for persistent AF with 
structural heart disease. For the comparison of dronedarone 
with class Ic drugs, the ICERs were £20,003 per QALY 
gained (incremental cost £1980 and incremental benefit 
0.10 QALYs) for paroxysmal AF with no structural heart 
disease and £20,761 per QALY gained (incremental cost 
£2069 and incremental benefit 0.10 QALYs) for persistent 
AF with no structural heart disease. For the comparison of 
dronedarone with sotalol, the ICERs ranged from £1929 
to £2197 per QALY gained (incremental costs £3986 and 
£4384 and incremental benefits 2.07 and 2.00 QALYs for 
these two ICERs respectively) (depending on the type of AF 
and the presence or absence of underlying heart disease). 
Further analysis by the Economic Review Group of NICE 
concluded that the model hinged on the assumption that 
dronedarone lowers mortality and that regrettably it does 
not specifically account for a lower rate of hospitalizations 
related to the drug.54
Unfortunately, not all patients with AF benefit from this 
agent. So in the study of dronedarone administered to patients 
with a recent heart failure hospitalization, dronedarone was 
associated with increased mortality and the study was ter-
minated early.55 A similar outcome was seen in the cohort 
of AF patients suffering from the persistent form of this 
condition who also had history of reduced left ventricular 
ejection fraction and congestive heart failure.56
Dronedarone is not free of interactions – it increases 
the levels of dabigatran, a novel oral anticoagulant, which 
may increase the risk of bleeding in this growing group of 
patients. It has been associated with significant liver toxicity 
and requires routine follow-up of the liver function studies.57 
Finally, it is not as effective as amiodarone from the point 
of view of rhythm control, desired by some patients and 
physicians.58,59
Based on these limitations, the role of dronedarone 
promising at the time of its entry onto the market is less 
certain. Given available data it should be used in patients 
with   paroxysmal AF and without history of significant left 
ventricular dysfunction, or congestive heart failure symptoms 
who are not at significant risk for liver disease. Patients 
treated with dronedarone should have their liver profile 
followed closely while on the drug. While the mindset of 
most physicians involves the use of dronedarone like any 
other antiarrhythmic agent, the data to support this practice 
is scant. On the other hand, dronedarone has excellent data 
to support its use in patients over 75 and those over 70 with 
one of the CHADS-2 risk factors for stroke for prognostic 
reasons, along the lines of beta blockers, statins, and ACE 
inhibitors, rather than to achieve rhythm control per se with 
excellent ICERs if the assumption of lower mortality holds 
true, or better still if hospitalizations are accounted for.
This subtlety was not appreciated by the The Canadian 
Expert Drug Advisory Committee (CEDAC), which recom-
mended not listing the drug for coverage.60 Their decision 
was based on the fact that dronedarone was several times 
more expensive than amiodarone while being inferior as 
an antiarrhythmic agent. The Committee felt that the evi-
dence for dronedarone being safer than amiodarone was 
not substantiated well enough despite admitting that the 
risk of adverse neurological and thyroid events was lower 
among patients treated with dronedarone. They did not take 
into account the fact that there is no data that amiodarone, 
the most potent antiarrhythmic agent on the market, has no 
data for reduction in hospitalizations, and, in fact, has data 
to the contrary.61 Dronedarone was also turned down by the 
British National Institute for Health and Clinical Excellence 
for similar reasons.
Conclusions
AF is increasingly prevalent in our society. It brings sig-
nificant morbidity and increases mortality. Treatment of 
AF and its sequelae is costly and needs to be contained. 
Strategies leading to a lower risk of embolic complications 
of AF and reduced AF-related hospitalizations need to be 
developed to meet these goals. While new medications 
addressing the embolic risks of AF are being introduced on 
the market, dronedarone, a novel antiarrhythmic agent, has 
been shown to both reduce the risk of stroke and the rate of 
hospital presentations and admissions among the patients 
suffering from AF. Although its use may be more limited 
than initially expected, it will likely reduce the cost of care 
for appropriately selected AF patients. Future after-market 
studies similar to that reported by the Humana registry would 
shed further light on whether dronedarone can indeed lower 
the cost of AF care in our society.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
76
Khaykin and ShamissClinicoEconomics and Outcomes Research 2012:4
  20.  Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ. Cost of 
an emerging epidemic: an economic analysis of atrial fibrillation in the 
UK. Heart. 2004;90(3):286–292.
  21.  Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy 
to prevent stroke in patients who have nonvalvular atrial fibrillation. 
Ann Intern Med. 2007;146(12):857–867.
  22.  ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, et al. Effect of 
clopidogrel added to aspirin in patients with atrial fibrillation. N Engl 
J Med. 2009;360(20):2066–2078.
  23.  Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus   warfarin 
in patients with atrial fibrillation. N Engl J Med. 2009;361(12): 
1139–1151.
  24.  Blackshear JL, Odell JA. Appendage obliteration to reduce stroke 
in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 
1996;61(2):755–759.
  25.  Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percuta-
neous left atrial appendage closure: results from the Watchman Left 
Atrial Appendage System for Embolic Protection in Patients with AF 
(PROTECT AF) clinical trial and the Continued Access Registry. 
Circulation. 2011;123(4):417–424.
  26.  Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, 
  Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial 
fibrillation in the United States. Value Health. 2006;9(5):348–356.
  27.  Bruggenjurgen B, Rossnagel K, Roll S, et al. The impact of atrial fibril-
lation on the cost of stroke: the berlin acute stroke study. Value Health. 
2007;10(2):137–143.
  28.  Canadian Institute for Health Information. The Cost of Acute Care 
Hospital Stays by Medical Condition in Canada, 2004–2005. Available 
from: http://secure.cihi.ca/cihiweb/products/nhex_acutecare07_e.pdf. 
Accessed December 29, 2011.
  29.  Wu EQ, Birnbaum HG, Mareva M, et al. Economic burden and co-
morbidities of atrial fibrillation in a privately insured population. Curr 
Med Res Opin. 2005;21(10):1693–1699.
  30.  Naccarelli GV , Johnston SS, Lin J, Patel PP, Schulman KL. Cost bur-
den of cardiovascular hospitalization and mortality in ATHENA-like 
patients with atrial fibrillation/atrial flutter in the United States. Clin 
Cardiol. 2010;33(5):270–279.
  31.  Reinhold T, Lindig C, Willich SN, Bruggenjurgen B. The costs of 
atrial fibrillation in patients with cardiovascular comorbidities – a 
longitudinal analysis of German health insurance data. Europace. 
2011;13(9):1275–1280.
  32.  Holstenson E, Ringborg A, Lindgren P, et al. Predictors of costs related 
to cardiovascular disease among patients with atrial fibrillation in five 
European countries. Europace. 2011;13(1):23–30.
  33.  Khaykin Y, Morillo CA, Skanes AC, McCracken A, Humphries K, 
Kerr CR. Cost comparison of catheter ablation and medical therapy in 
atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18(9):907–913.
  34.  Moeremans K, Aliott E, Chillou Cd, Annemans L, Pen CL, Jong Pd. 
Second line pharmacological management of paroxysmal and persistent 
atrial fibrillation in france: a cost analysis. Value Health. 2000;3(6): 
407–416.
  35.  Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in 
high-risk patients with atrial fibrillation who are not adequately anti-
coagulated. Stroke. 2009;40(1):235–240.
  36.  Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus 
  warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11): 
981–992.
  37.  Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of 
dabigatran etexilate for the prevention of stroke and systemic embolism 
in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 
2011;105(5):908–919.
  38.  Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate 
versus warfarin in management of non-valvular atrial fibrillation in 
UK context: quantitative benefit-harm and economic analyses. BMJ. 
2011;343:d6333.
  39.  Shah SV , Gage BF. Cost-effectiveness of dabigatran for stroke pro-
phylaxis in atrial fibrillation. Circulation. 2011;123(22):2562–2570.
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  Camm AJ, Obel OA. Epidemiology and mechanism of atrial fibrillation 
and atrial flutter. Am J Cardiol. 1996;78(8A):3–11.
  2.  Naccarelli GV , Varker H, Lin J, Schulman KL. Increasing prevalence 
of atrial fibrillation and flutter in the United States. Am J Cardiol. 
2009;104(11):1534–1539.
  3.  Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed 
atrial fibrillation in adults: national implications for rhythm 
  management and stroke prevention: the AnTicoagulation and Risk 
Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18): 
2370–2375.
  4.  Bialy D, Lehmann MH, Schumacher DN, Steinman RT, Meissner MD. 
Hospitalization for arrhythmias in the United States: importance of atrial 
fibrillation. J Am Coll Cardiol. 1992;19(3):41A.
  5.  Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. 
Impact of atrial fibrillation on the clinical course of hypertrophic 
  cardiomyopathy. Circulation. 2001;104(21):2517–2524.
  6.  Wolf PA, Mitchell JB, Baker CS, Kannel WB, D’Agostino RB. Impact 
of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern 
Med. 1998;158(3):229–234.
  7.  Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification 
schemes for predicting stroke and thromboembolism in patients with 
atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
  8.  Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, 
Levy D. Impact of atrial fibrillation on the risk of death: the Framingham 
Heart Study. Circulation. 1998;98(10):946–952.
  9.  Ringborg A, Nieuwlaat R, Lindgren P, et al. Costs of atrial fibrillation 
in five European countries: results from the Euro Heart Survey on atrial 
fibrillation. Europace. 2008;10(4):403–411.
  10.  Chung MK, Shemanski L, Sherman DG, et al. Functional status in 
rate- versus rhythm-control strategies for atrial fibrillation: results of 
the Atrial Fibrillation Follow-Up Investigation of Rhythm Manage-
ment (AFFIRM) Functional Status Substudy. J Am Coll Cardiol. 
2005;46(10):1891–1899.
  11.  Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus 
rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up 
Investigation of Rhythm Management (AFFIRM) Study. Circulation. 
2004;109(12):1509–1513.
  12.  Guglin M, Chen R, Curtis AB. Sinus rhythm is associated with fewer 
heart failure symptoms: insights from the AFFIRM trial. Heart Rhythm. 
2010;7(5):596–601.
  13.  Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence 
of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. 
N Engl J Med. 2000;342(13):913–920.
  14.  Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based 
review of clinical indications. JAMA. 2007;298(11):1312–1322.
  15.  Nattel S, Singh BN. Evolution, mechanisms, and classification 
of antiarrhythmic drugs: focus on class III actions. Am J Cardiol. 
1999;84(9A):11R–19R.
  16.  Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic 
drug therapy and radiofrequency catheter ablation in patients with 
paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 
2010;303(4):333–340.
  17.  Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on 
the methods, efficacy, and safety of catheter ablation for human atrial 
fibrillation. Circ Arrhythm Electrophysiol. 2010;3(1):32–38.
  18.  Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus 
strict rate control in patients with atrial fibrillation. N Engl J Med. 
2010;362(15):1363–1373.
  19.  Gillis AM, Verma A, Talajic M, Nattel S, Dorian P. Canadian Cardio-
vascular Society atrial fibrillation guidelines 2010: rate and rhythm 
management. Can J Cardiol. 2011;27(1):47–59.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
77
Dronedarone and cost of AF managementClinicoEconomics and Outcomes Research
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journal
ClinicoEconomics & Outcomes Research is an international, peer-
reviewed open-access journal focusing on Health Technology Assess-
ment, Pharmacoeconomics and Outcomes Research in the areas of 
diagnosis, medical devices, and clinical, surgical and pharmacological 
intervention. The economic impact of health policy and health systems 
organization also constitute important areas of coverage. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
ClinicoEconomics and Outcomes Research 2012:4
  40.  Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial 
fibrillation by ectopic beats originating in the pulmonary veins. N Engl 
J Med. 1998;339(10):659–666.
  41.  Nademanee K, McKenzie J, Kosar E, et al. A new approach for cath-
eter ablation of atrial fibrillation: mapping of the electrophysiologic 
substrate. J Am Coll Cardiol. 2004;43(11):2044–2053.
  42.  Nakagawa H, Scherlag BJ, Patterson E, Ikeda A, Lockwood D, 
  Jackman WM. Pathophysiologic basis of autonomic ganglionated 
plexus ablation in patients with atrial fibrillation. Heart Rhythm. 2009; 
6(12 Suppl):S26–S34.
  43.  Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation 
vs antiarrhythmic drugs as first-line treatment of symptomatic atrial 
fibrillation: a randomized trial. JAMA. 2005;293(21):2634–2640.
  44.  Jais P, Cauchemez B, Macle L, et al. Catheter ablation versus anti-
arrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 
2008;118(24):2498–2505.
  45.  Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare 
resource utilization and costs associated with recurrent episodes of 
atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol. 
2007;18(6):628–633.
  46.  Chan PS, Vijan S, Morady F, Oral H. Cost-effectiveness of radiof-
requency catheter ablation for atrial fibrillation. J Am Coll Cardiol. 
2006;47(12):2513–2520.
  47.  Eckard N, Davidson T, Walfridsson H, Levin AL. Cost-effectiveness 
of catheter ablation treatment for patients with symptomatic atrial 
fibrillation. J Atr Fibrillation. 2009;1(8):461–470.
  48.  McKenna C, Palmer S, Rodgers M, et al. Cost-effectiveness of radiof-
requency catheter ablation for the treatment of atrial fibrillation in the 
United Kingdom. Heart. 2009;95(7):542–549.
  49.  Reynolds MR, Zimetbaum P, Josephson ME, Ellis E, Danilov T,   
Cohen DJ. Cost-effectiveness of radiofrequency catheter ablation com-
pared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. 
Circ Arrhythm Electrophysiol. 2009;2(4):362–369.
  50.  Kathofer S, Thomas D, Karle CA. The novel antiarrhythmic drug 
dronedarone: comparison with amiodarone. Cardiovasc Drug Rev. 
2005;23(3):217–230.
  51.  Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of 
ventricular rate in permanent atrial fibrillation: the Efficacy and safety 
of dRonedArone for the cOntrol of ventricular rate during atrial fibril-
lation (ERATO) study. Am Heart J. 2008;156(3):527. e521–e529.
  52.  Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of drone-
darone on cardiovascular events in atrial fibrillation. N Engl J Med. 
2009;360(7):668–678.
  53.  Torp-Pedersen C, Crijns HJ, Gaudin C, Page RL, Connolly SJ, 
Hohnloser SH; ATHENA Investigators. Impact of dronedarone on 
hospitalization burden in patients with atrial fibrillation: results from 
the ATHENA study. Europace. 2011;13(8):1118–1126.
  54.  NHS National Institute for Health and Clinical Excellence. Dronedarone 
for the treatment of nonpermanent atrial fibrillation (TA197). 2010. 
Available from: http://publications.nice.org.uk/dronedarone-for-the-
treatment-of-nonpermanent-atrial-fibrillation-ta197/guidance. Accessed 
December 10, 2011.
  55.  Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality 
after dronedarone therapy for severe heart failure. N Engl J Med. 
2008;358(25):2678–2687.
  56.  FDA. FDA Drug Safety Communication: Multaq (dronedarone) and 
increased risk of death and serious cardiovascular adverse events. 2011. 
Available from: http://www.fda.gov/Drugs/DrugSafety/ucm264059.
htm. Accessed November 2, 2011.
  57.  FDA. FDA Drug Safety Communication: Severe liver injury associated 
with the use of dronedarone (marketed as Multaq). 2011. Available 
from: http://www.fda.gov/drugs/drugsafety/ucm240011.htm. Accessed 
November 2, 2011.
  58.  Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, 
Kong DF. Comparative efficacy of dronedarone and amiodarone for 
the maintenance of sinus rhythm in patients with atrial fibrillation.   
J Am Coll Cardiol. 2009;54(12):1089–1095.
  59.  Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM.   
A short-term, randomized, double-blind, parallel-group study to   
evaluate the efficacy and safety of dronedarone versus amiodarone 
in patients with persistent atrial fibrillation: the DIONYSOS study.   
J Cardiovasc Electrophysiol. 2010;21(6):597–605.
  60.  Canadian Agency for Drugs and Technologies in Health. CEDAC 
FINAL RECOMMENDATION on DRONEDARONE HYDROCHLO-
RIDE. Common Drug Review. 2010. Available from: http://www.
cadth.ca/media/cdr/complete/cdr_complete_Multaq_May-31-2010.
pdf. Accessed December 10, 2011.
  61.  Saksena S, Slee A, Waldo AL, et al. Cardiovascular outcomes in the 
AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm 
Management). An assessment of individual antiarrhythmic drug thera-
pies compared with rate control with propensity score-matched analyses. 
J Am Coll Cardiol. 2011;58(19):1975–1985.
  62.  Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH.   
Dronedarone for prevention of atrial fibrillation: a dose-ranging study. 
Eur Heart J. 2003;24(16):1481–1487.
  63.  Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality 
after dronedarone therapy for severe heart failure. N Engl J Med. 
2008;358(25):2678–2687.
  64.  Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for mainte-
nance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 
2007;357(10):987–999.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
78
Khaykin and Shamiss